Chondrosarcoma

Chondrosarcoma is the third most common primary malignant bone tumour after multiple myeloma and osteosarcoma, accounting for approximately 20–27% of all primary bone sarcomas. It is a malignant tumour arising from chondrogenic cells that produces cartilage matrix but not bone. Unlike osteosarcoma and Ewing sarcoma, chondrosarcoma is predominantly a tumour of adult and middle-aged patients, with a peak incidence in the 4th–6th decades. It is characterised by relative resistance to conventional chemotherapy and radiotherapy, making surgery the primary — and often sole — treatment modality. The spectrum of chondrosarcoma ranges from low-grade lesions with indolent behaviour to high-grade tumours with aggressive metastatic potential.

• Clinical features: slowly progressive, deep, aching pain — often present for months to years before diagnosis (low-grade chondrosarcoma is an indolent tumour); pain in an adult with a cartilage lesion is the most important red flag for malignant transformation from enchondroma; palpable mass in some cases (especially peripheral secondary chondrosarcoma from osteochondroma); pathological fracture in aggressive Grade 3 or dedifferentiated tumours; neurological symptoms if spinal or pelvic involvement; NOTE — Grade 1 central chondrosarcoma (ACT) may be painless and discovered incidentally, creating diagnostic difficulty in distinguishing it from enchondroma
• Plain radiographic features: ring-and-arc (arcuate) calcification within a lobular lytic lesion — the cartilage matrix pattern; endosteal scalloping — crucial finding; the depth and extent of endosteal scalloping is the most important plain radiograph measurement for distinguishing enchondroma from chondrosarcoma (>2/3 cortical thickness scalloping = chondrosarcoma); cortical thickening or destruction; periosteal reaction in higher-grade tumours; soft tissue mass (Grade 2–3 and dedifferentiated)
• MRI features: T2/STIR — high signal lobular lesion (water content of hyaline cartilage); ring-and-arc enhancement on gadolinium-enhanced T1 (peripheral and septal enhancement around cartilage lobules); features favouring malignancy over enchondroma — intralesional cysts or necrosis, cortical breakthrough, extraosseous soft tissue extension, high signal extending beyond the lesion; the pattern of enhancement does NOT reliably distinguish low-grade chondrosarcoma from enchondroma — this distinction requires combined clinical, radiological, and histological assessment at a specialist centre

The distinction between enchondroma and Grade 1 central chondrosarcoma (atypical cartilaginous tumour) is one of the most diagnostically challenging problems in orthopaedic oncology. There is a recognised diagnostic spectrum from `borderline` lesions through to unequivocal malignancy, and histological assessment alone is often insufficient — a multidisciplinary correlation of clinical, radiological, and histological features is required.

• WHO 2020 classification change: the term `Grade 1 chondrosarcoma` of long bones and the appendicular skeleton has been renamed `atypical cartilaginous tumour (ACT)`; this reflects the fact that these lesions virtually never metastasise from long bone locations and curettage (intralesional) is often adequate treatment; however, Grade 1 chondrosarcoma of the pelvis, axial skeleton, and skull base retains the malignant classification — these DO require wide excision due to local recurrence risk and occasional metastatic potential in these locations

• Biopsy principles: biopsy of cartilage tumours is technically challenging — the cartilage matrix is paucicellular and sampling error is common; biopsy results must ALWAYS be correlated with clinical and imaging findings; an `enchondroma` on biopsy does not exclude chondrosarcoma if the imaging and clinical features are suspicious; the biopsy must be planned with the definitive surgical approach in mind (the biopsy tract must be within the planned resection zone); do NOT biopsy a peripheral osteochondroma cap or an obviously benign lesion — surgical excision is both diagnostic and therapeutic
• Surgical management by grade and location: Grade 1 ACT (long bone appendicular) — intralesional curettage + cementation (adequate for most cases; wide excision reserved for large lesions with aggressive features or those causing fracture risk); Grade 1 chondrosarcoma (pelvis/axial) — WIDE excision required (local recurrence risk is higher; pelvic excision challenging); Grade 2 and Grade 3 — wide surgical excision is mandatory; the surgical margin quality is the most important determinant of local recurrence risk in all grades; adjuvant chemotherapy has no proven benefit for conventional chondrosarcoma; radiotherapy has limited efficacy for conventional chondrosarcoma (cartilage is relatively radioresistant)
• Chondrosarcoma is surgery-only: conventional chondrosarcoma (Grade 1, 2, 3 central/peripheral) does NOT respond to conventional chemotherapy or radiotherapy; surgery is the only effective treatment modality; this fundamental difference from osteosarcoma and Ewing sarcoma means that there is no role for neoadjuvant chemotherapy in conventional chondrosarcoma; exceptions — dedifferentiated chondrosarcoma (the high-grade dedifferentiated component may be treated with osteosarcoma-type chemotherapy protocols) and mesenchymal chondrosarcoma (may receive Ewing/rhabdomyosarcoma protocols)

• Chondrosarcoma: 3rd most common primary bone malignancy; adults 4th–6th decade; surgery ONLY (no effective chemotherapy or RT for conventional chondrosarcoma); grade determines prognosis (Grade 1 5-year OS 90%; Grade 3 30%)
• Central chondrosarcoma: intramedullary; ring-and-arc calcification; pelvis + proximal femur most common; IDH1/IDH2 mutations (~55%); Grade 1 = ACT in appendicular skeleton (curettage) vs pelvis (wide excision)
• ACT/Grade 1 long bone: WHO 2020 — renamed atypical cartilaginous tumour; virtually never metastasises from appendicular long bones; intralesional curettage adequate; Grade 1 pelvis/axial — still requires wide excision
• Dedifferentiated chondrosarcoma: bimorphic — low-grade cartilage + high-grade non-cartilaginous sarcoma at abrupt transition; IDH + TP53 mutations; 5-year OS ~10–20%; worst prognosis; chemotherapy for high-grade component
• Clear cell chondrosarcoma: EPIPHYSEAL location (unique among chondrosarcomas and cartilage tumours generally); low-grade; wide excision curative; clear cytoplasm on histology; mimics chondroblastoma
• Mesenchymal chondrosarcoma: young adults; biphasic histology (cartilage islands + small round blue cells); HEY1-NCOA2 fusion; late metastases (20+ years); chemotherapy used
• Secondary peripheral chondrosarcoma: from osteochondroma cap; cap >2 cm in adult = suspicious; wide excision; EXT1/EXT2 mutations; generally low-grade
• Endosteal scalloping >2/3 cortical width: KEY radiographic feature distinguishing chondrosarcoma from enchondroma; also: pain in adult + size >5 cm + progressive growth + cortical breach = chondrosarcoma
• Biopsy sampling error: cartilage paucicellular → easy to miss malignancy; biopsy does NOT exclude chondrosarcoma if imaging/clinical suspicious; multidisciplinary correlation mandatory
• Chemotherapy: NO benefit for conventional chondrosarcoma (all grades); RT limited benefit (cartilage radioresistant); surgery only; exceptions: dedifferentiated (chemo for high-grade component) and mesenchymal (Ewing-type chemo)